Novanta completes $1.2B acquisition of Riverpoint Medical; expects $0.18-$0.25 adjusted EPS accretion in 2027

NOVANTA INC

Acquired Riverpoint Medical for ~$1.2B cash at closing; additional $250M milestone payment due by Jan 8, 2027.
Funded with $616M in borrowings under credit facilities; total consolidated debt now $854.7M.
Deal expected to double recurring medical consumables revenue to ~$300M and push medical end-market to 60% of total revenue.
Expects $0.18-$0.25 adjusted EPS accretion in 2027, high single-digit ROIC by year three, and immediate accretion to margins.
Riverpoint is a category leader in minimally invasive surgical consumables for sports medicine, trauma, and cardiovascular applications.

item 2.01 item 1.01 item 2.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.